Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MTOR | P42345 | 16/20 | 0.61 |
| ▸ | PIK3CA | P42336 | 15/20 | 0.61 |
| ▸ | PIK3CD | O00329 | 3/20 | 0.53 |
| ▸ | CHEK1 | O14757 | 1/20 | 0.51 |
| ▸ | ATR | Q13535 | 1/20 | 0.51 |
| ▸ | PDCD1 | Q15116 | 1/20 | 0.51 |
| ▸ | ATRIP | Q8WXE1 | 1/20 | 0.51 |
| ▸ | CD274 | Q9NZQ7 | 1/20 | 0.51 |
| ▸ | PIK3CG | P48736 | 2/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4270408 | 1.00 | MTOR (0.61) | MTORPIK3CAPIK3CDCHEK1ATR | |
| SCHEMBL3984055 | 1.00 | MTOR (0.61) | MTORPIK3CAPIK3CDCHEK1ATR | |
| SCHEMBL27773619 | 0.87 | PIK3CA (0.58) | MTORPIK3CAPIK3CDCHEK1ATR | |
| SCHEMBL4991670 | 0.84 | PIK3CA (0.78) | MTORPIK3CAPIK3CDPIK3CG | |
| SCHEMBL3983421 | 0.81 | PIK3CA (0.73) | MTORPIK3CAPIK3CDPIK3CG | |
| SCHEMBL3994146 | 0.80 | PIK3CA (0.59) | MTORPIK3CAPIK3CDPIK3CG | |
| SCHEMBL56413 | 0.80 | PIK3CA (0.65) | MTORPIK3CAPIK3CG | |
| SCHEMBL3986335 | 0.80 | PIK3CA (0.59) | MTORPIK3CAPIK3CDPIK3CG | |
| SCHEMBL54828 | 0.79 | PIK3CA (0.57) | MTORPIK3CAPIK3CG | |
| SCHEMBL3985124 | 0.79 | PIK3CA (0.60) | MTORPIK3CAPIK3CG |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2078021-A2 | PYRAZOLOPYRIMIDINE ANALOGS AND THEIR USE AS MTOR KINASE AND PI3 KINASE INHIBITORS | Wyeth a Corporation of the State of Delaware (US) | 2009-07-15 | — | — | EP | claimed |
| WO-2008115974-A2 | PYRAZOLOPYRIMIDINE ANALOGS AND THEIR USE AS MTOR KINASE AND PI3 KINASE INHIBITORS | WYETH (US) | 2008-09-25 | — | — | WO | claimed |
| US-20080234262-A1 | PYRAZOLOPYRIMIDINE ANALOGS AND THEIR USE AS MTOR KINASE AND PI3 KINASE INHIBITORS | WYETH (US) | 2008-09-25 | — | — | US | claimed |
| CN-101675051-A | Pyrazolopyrimidine analogs and their use as mtor kinase and pi3 kinase inhibitors | WYETH CORP | 2010-03-17 | — | — | CN | disclosed |
| EP-2078021-A2 | PYRAZOLOPYRIMIDINE ANALOGS AND THEIR USE AS MTOR KINASE AND PI3 KINASE INHIBITORS | Wyeth a Corporation of the State of Delaware (US) | 2009-07-15 | — | — | EP | disclosed |
| WO-2008115974-A2 | PYRAZOLOPYRIMIDINE ANALOGS AND THEIR USE AS MTOR KINASE AND PI3 KINASE INHIBITORS | WYETH (US) | 2008-09-25 | — | — | WO | disclosed |
| WO-2008115974-A2 | PYRAZOLOPYRIMIDINE ANALOGS AND THEIR USE AS MTOR KINASE AND PI3 KINASE INHIBITORS | WYETH (US) | 2008-09-25 | — | — | WO | disclosed |
| US-20080234262-A1 | PYRAZOLOPYRIMIDINE ANALOGS AND THEIR USE AS MTOR KINASE AND PI3 KINASE INHIBITORS | WYETH (US) | 2008-09-25 | — | — | US | disclosed |
| US-20080234262-A1 | PYRAZOLOPYRIMIDINE ANALOGS AND THEIR USE AS MTOR KINASE AND PI3 KINASE INHIBITORS | WYETH (US) | 2008-09-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080234262-A1 | PYRAZOLOPYRIMIDINE ANALOGS AND THEIR USE AS MTOR KINASE AND PI3 KINASE INHIBITORS | MTOR, PIK3CA, PDPK1 | MTOR 1/4885PIK3CA 2/4885PIK3CD 7/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.